Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.23B P/E - EPS this Y -33.30% Ern Qtrly Grth -
Income -105.37M Forward P/E -12.57 EPS next Y 20.50% 50D Avg Chg 25.00%
Sales 31.07M PEG - EPS past 5Y - 200D Avg Chg 63.00%
Dividend N/A Price/Book 11.75 EPS next 5Y - 52W High Chg -5.00%
Recommedations 3.00 Quick Ratio 10.70 Shares Outstanding 114.79M 52W Low Chg 298.00%
Insider Own 0.52% ROA -22.05% Shares Float 96.64M Beta 0.32
Inst Own 103.13% ROE -64.17% Shares Shorted/Prior 5.85M/9.30M Price 12.57
Gross Margin -160.03% Profit Margin - Avg. Volume 1,852,533 Target Price 32.50
Oper. Margin -74,557.90% Earnings Date May 13 Volume 787,234 Change -2.56%
About CymaBay Therapeutics Inc.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

CymaBay Therapeutics Inc. News
03/22/24 Gilead Sciences Announces Completion of Acquisition of CymaBay
03/11/24 Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain
03/04/24 CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
02/28/24 CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
02/28/24 CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
02/21/24 The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
02/20/24 CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/15/24 Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
02/15/24 Director Janet Dorling Sells 6,000 Shares of CymaBay Therapeutics Inc (CBAY)
02/13/24 Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
02/12/24 CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion
02/12/24 Stocks to Watch Monday: Diamondback, CymaBay, Gilead, Tod's
02/12/24 Why Wall Street Was Lukewarm on Gileadโ€™s $4.3 Billion Liver-Drug Deal
02/12/24 Gilead to Buy Liver Disease Biotech After String of Disappointments
02/12/24 CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal
02/12/24 CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
02/12/24 Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
02/12/24 UPDATE 2-Drugmaker Gilead to acquire CymaBay for $4.3 bln
02/12/24 Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
02/12/24 Gilead to buy CymaBay in $4.3B deal for liver disease drug
CBAY Chatroom

User Image DaBullRunner Posted - 2 weeks ago

$ATHE as you can see I predicted $CBAY getting bought out from the $4โ€™s๐Ÿ‘‡๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ If the presentation comes out positive as it did last time This ticker could be an M&A target and at a major premium ๐Ÿฆ๐Ÿฆ๐Ÿฆ๐Ÿฆ $LXEH $RENT $CADL all paying me very well ๐Ÿ™

User Image DaBullRunner Posted - 2 weeks ago

$ATHE smart money not selling a single share under $5 This is a potential double digit ticker like I said $CBAY was before they got bought out

User Image dbr_island Posted - 2 weeks ago

Predicted that $CBAY was gonna get acquired๐Ÿ‘‡๐Ÿง™๐Ÿ”ฎ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ Now if $IGC keeps it up with their Phase 2-3 in ALZHEIMERS they could be the next to get acquired ๐Ÿ”ฎ๐Ÿง™๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ

User Image TravisBking87 Posted - 03/31/24

$ALT $CBAY $AQST $DRCT I believe in Jack wisdom and it did help me a lot in my trades!

User Image jacksparo Posted - 03/29/24

$ALT It is turn around momentum for us as a long term holder here. You know I got my history in reaching my price targets! In $DRCT $AQST $CBAY And a lot others I canโ€™t put them all in one postโœ…! But yes I am seeing a good time coming for ALT ๐Ÿ“ˆ๐Ÿ“ˆ! Wait for my incoming update about this via the email team ๐Ÿ’ฐ๐Ÿ’ต๐Ÿš€๐Ÿ’ฐ๐Ÿ’ต๐Ÿš€!

User Image Ohzipit Posted - 03/29/24

$ARDX RJF most recent comments dated 03/06. SS same analyst $CBAY @$5 $VKTX in the single digits, $RNA under single digits.

User Image Thinklikethecompany Posted - 03/28/24

$CBAY

User Image NEWBIGTECH Posted - 03/28/24

$SLS I hope all my friends are up to date on this amazing company. Do your own dd. I have been in $CBAY, $OPK $ATHE and others, this is great news on the cancer front. $SLS IS UNDERVALUED.

User Image Bjaccarini Posted - 03/28/24

$CBAY does anyone know when the second tender is to take place

User Image dbr_island Posted - 4 weeks ago

$YTEN red to green confirmed!!! ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ Iโ€™m telling you BIG AG is eyeing this company imo Read what I said about $CBAY ๐Ÿ‘‡๐Ÿง™๐Ÿ”ฎ๐Ÿ’ฐ๐Ÿ’ฐ

User Image CharlieBPupp Posted - 1 month ago

$HOOD is this going up because they locked up my $CBAY shares?

User Image Cal1f0rn1aBay Posted - 1 month ago

$KRTX $SPLK $AYX $CBAY $BKCC

User Image Yourmatefromdownunder Posted - 1 month ago

$CBAY Not happy! That was a BS buy out at far below the real value of the company, yes I made a boat load of cash but it should have been much much higher, as usual shareholders got ripped off!

User Image Logout Posted - 1 month ago

$GILD $ASMB $CBAY

User Image StupediaTrades Posted - 1 month ago

$CBAY Each week we take a look at NASH Chart Watchlist and grade them A,B or C This Continues in beat mode.Congrats to all . Follow watchlist Grading by clicking the link in my profile.

User Image hockeypuckdude Posted - 1 month ago

$CBAY The release states that it should take a few business days

User Image hockeypuckdude Posted - 1 month ago

$CBAY

User Image immuz Posted - 1 month ago

$CBAY Anyone receive their cash yet?

User Image Practical Posted - 1 month ago

$CBAY I did not do anything to the tender. What happens to my holding now?

User Image immuz Posted - 1 month ago

$CBAY Thank you Behzad for another 800%+ return.

User Image Stock_Titan Posted - 1 month ago

$GILD $CBAY Gilead Sciences Announces Completion of Acquisition of CymaBay https://www.stocktitan.net/news/GILD/gilead-sciences-announces-completion-of-acquisition-of-cyma-xw2u4y51n430.html

User Image hockeypuckdude Posted - 1 month ago

$CBAY Hockeypuckdude signing off. Best wishes to all. Special thanks to Sujal S. & his incredible team for strategically putting the Seladelpar program and the company as a whole back together again.

User Image hockeypuckdude Posted - 1 month ago

$CBAY 77% voted in favor per SEC.GOV filings made this morning and per the the Depository. The deal should be completed on March 22nd. All of this is available to read on EDGAR.

User Image hockeypuckdude Posted - 1 month ago

$CBAY No news yet.

User Image tradethehalt Posted - 1 month ago

$CBAY trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $32.48 Vol: 8.36M.

User Image tomRussell80 Posted - 1 month ago

$CBAY goodbye - it was a nice ride

User Image Yourmatefromdownunder Posted - 1 month ago

$VKTX Holding on to every share, this has a long way to go before I think about selling a single share. Have had some big scores lately, several picks bought out, $CBAY was disappointing though, although I made big $$$$ I feel they gave it away at $32.50, $GILD STOLE IT!

User Image hockeypuckdude Posted - 1 month ago

$CBAY 'Twas the night before closing...and all through the house...

User Image JohnUtah9 Posted - 1 month ago

$GILD is a $100B company. The $cbay addition is a blip on their radar. However I do own some GILD already but not to the extent of my former $cbay position.

User Image JohnUtah9 Posted - 1 month ago

$CBAY 100% agree, but what can a small shareholder do about it. Should have been $40-$45 ps

Analyst Ratings
HC Wainwright & Co. Neutral Feb 29, 24
Leerink Partners Market Perform Feb 20, 24
LifeSci Capital Market Perform Feb 14, 24
UBS Neutral Feb 14, 24
Piper Sandler Neutral Feb 14, 24
BTIG Neutral Feb 13, 24
HC Wainwright & Co. Neutral Feb 13, 24
Raymond James Market Perform Feb 13, 24
B. Riley Securities Neutral Feb 13, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
McWherter Charles President of R&D President of R&D Jan 19 Sell 23.67 18,403 435,599 15,000 01/22/24
McWherter Charles President of R&D President of R&D Jan 19 Option 5.26 18,403 96,800 18,125 01/22/24
Menold Daniel Vice President, Fina.. Vice President, Finance Jan 16 Sell 23.58 10,000 235,800 01/16/24
Menold Daniel Vice President, Fina.. Vice President, Finance Jan 16 Option 4.05 10,000 40,500 10,000 01/16/24
Quinlan Paul T General Counsel General Counsel Jan 16 Sell 23.58 5,000 117,900 01/16/24
Quinlan Paul T General Counsel General Counsel Jan 16 Option 2.94 5,000 14,700 5,000 01/16/24
Dorling Janet Director Director Jan 10 Sell 23.86 6,000 143,160 01/10/24
Dorling Janet Director Director Jan 10 Option 4.63 6,000 27,780 6,000 01/10/24
McWherter Charles President of R&D President of R&D Dec 18 Sell 21.48 11,332 243,411 15,000 12/18/23
McWherter Charles President of R&D President of R&D Dec 18 Option 5 11,332 56,660 21,504 12/18/23
Shah Sujal Chief Executive Offi.. Chief Executive Officer Dec 11 Sell 20.4 64,865 1,323,246 171,301 12/11/23
Shah Sujal Chief Executive Offi.. Chief Executive Officer Dec 11 Option 5 64,865 324,325 172,191 12/11/23
Dorling Janet Director Director Dec 11 Sell 20.07 6,000 120,420 12/11/23
Dorling Janet Director Director Dec 11 Option 4.63 6,000 27,780 6,000 12/11/23
McWherter Charles President of R&D President of R&D Nov 17 Sell 18.28 11,342 207,332 15,000 11/17/23
McWherter Charles President of R&D President of R&D Nov 17 Option 5 11,342 56,710 26,342 11/17/23
Menold Daniel Vice President, Fina.. Vice President, Finance Nov 15 Sell 17.38 11/17/23
Menold Daniel Vice President, Fina.. Vice President, Finance Nov 15 Option 3.45 17,500 60,375 17,500 11/17/23
Quinlan Paul T General Counsel General Counsel Nov 15 Sell 17.38 5,000 86,900 11/17/23
Quinlan Paul T General Counsel General Counsel Nov 15 Option 2.94 5,000 14,700 5,000 11/17/23
McWherter Charles President of R&D President of R&D Oct 18 Sell 14.07 21,743 305,924 15,000 10/18/23
McWherter Charles President of R&D President of R&D Oct 18 Option 5 21,743 108,715 36,743 10/18/23
Menold Daniel Vice President, Fina.. Vice President, Finance Oct 16 Sell 13.76 10/18/23
Menold Daniel Vice President, Fina.. Vice President, Finance Oct 16 Option 3.45 17,500 60,375 17,500 10/18/23
Quinlan Paul T General Counsel General Counsel Oct 16 Option 2.94 5,000 14,700 5,000 10/18/23
Quinlan Paul T General Counsel General Counsel Oct 16 Sell 13.76 5,000 68,800 10/18/23
Shah Sujal Chief Executive Offi.. Chief Executive Officer Oct 09 Sell 14.2 64,861 921,026 171,301 10/10/23
Shah Sujal Chief Executive Offi.. Chief Executive Officer Oct 09 Option 5 64,861 324,305 236,162 10/10/23
EMSTER KURT VON Director Director Sep 29 Sell 15.68 15,921 249,641 90,000 09/29/23
EMSTER KURT VON Director Director Sep 29 Option 5 15,921 79,605 105,921 09/29/23
McWherter Charles President of R&D President of R&D Sep 18 Sell 16.22 21,746 352,720 15,000 09/19/23
McWherter Charles President of R&D President of R&D Sep 18 Option 5 21,746 108,730 36,746 09/19/23
Menold Daniel Vice President, Fina.. Vice President, Finance Sep 15 Sell 16.87 09/19/23
Menold Daniel Vice President, Fina.. Vice President, Finance Sep 15 Option 1.77 16,545 29,285 15,000 09/19/23
Quinlan Paul T General Counsel General Counsel Sep 15 Sell 16.87 53,000 894,110 09/19/23
Quinlan Paul T General Counsel General Counsel Sep 15 Option 2.94 53,000 155,820 24,000 09/19/23
McWherter Charles President of R&D President of R&D Aug 18 Option 5 21,746 108,730 36,746 08/18/23
McWherter Charles President of R&D President of R&D Aug 18 Sell 11.47 21,746 249,427 15,000 08/18/23
Menold Daniel Vice President, Fina.. Vice President, Finance Aug 15 Sell 12.02 08/16/23
Menold Daniel Vice President, Fina.. Vice President, Finance Aug 15 Option 5.53 15,500 85,715 7,000 08/16/23
Quinlan Paul T General Counsel General Counsel Aug 15 Sell 11.91 5,000 59,550 08/16/23
Quinlan Paul T General Counsel General Counsel Aug 15 Option 2.94 5,000 14,700 5,000 08/16/23
Menold Daniel Vice President, Fina.. Vice President, Finance Aug 09 Sell 12.35 20,945 258,671 08/11/23
Menold Daniel Vice President, Fina.. Vice President, Finance Aug 09 Option 5 20,945 104,725 20,945 08/11/23
McWherter Charles President of R&D President of R&D Jul 18 Sell 11.43 21,749 248,591 15,000 07/19/23
McWherter Charles President of R&D President of R&D Jul 18 Option 5 21,749 108,745 36,749 07/19/23
Quinlan Paul T General Counsel General Counsel Jul 14 Sell 11.81 5,000 59,050 07/14/23
Quinlan Paul T General Counsel General Counsel Jul 14 Option 2.94 5,000 14,700 5,000 07/14/23
McWherter Charles President of R&D President of R&D Jun 20 Sell 8.16 21,749 177,472 15,000 06/21/23
McWherter Charles President of R&D President of R&D Jun 20 Option 5 21,749 108,745 36,749 06/21/23